Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and agree to follow the study schedule and attend follow-up appointments
• People aged 18 or older (any gender)
• People diagnosed through imaging with oligometastatic esophageal squamous cell carcinoma — meaning a type of esophageal cancer that has spread to no more than 5 spots outside the main tumour, affecting no more than 2 other organs in the body, and has been present for more than 3 months
• People who have at least one tumour that can be measured on scans, based on standard medical criteria
• People with a life expectancy of at least 3 months
• People with a good general level of physical functioning (able to carry out daily activities with little or no restriction, as assessed by a standard medical scale)
• People whose liver, kidneys, and bone marrow are functioning well enough as shown by blood tests
• Women who could become pregnant must use appropriate contraception from the screening period until 3 months after stopping the study treatment, must not be breastfeeding, and must have a negative pregnancy test before starting; men must agree to use appropriate contraception during the trial and for 8 weeks after the last dose, or must have had a surgical sterilisation procedure

Who may not be able to join:

• People who have previously received certain immune checkpoint therapies (PD-1, PD-L1, or CTLA-4 antibodies) or certain anti-blood-vessel-growth drugs such as sunitinib, sorafenib, regorafenib, bevacizumab, imatinib, or apatinib
• People who have taken part in another drug clinical trial within the past 4 weeks, or who have recently received chemotherapy, radiotherapy, or other cancer treatments
• People with a high risk of bleeding
• People who have had an organ transplant in the past
• People with other conditions that make participation not possible (confirm with trial site)
• People with high blood pressure that cannot be controlled with a single medication, or that requires two or more blood pressure medications to manage
• People with significant heart problems, including moderate or severe reduced blood flow to the heart, certain abnormal heart rhythms, or moderate-to-severe heart failure
• People with an active or uncontrolled serious infection
• People with liver cirrhosis, serious liver disease, active hepatitis, or chronic hepatitis with a high viral load that requires antiviral treatment
• People whose kidneys require dialysis (haemodialysis or peritoneal dialysis)
• People with a history of immune deficiency conditions, including HIV, other inherited or acquired immune disorders, or a history of organ transplantation
• People who have a history of non-infectious lung inflammation that required steroid treatment, or who currently have non-infectious lung inflammation or interstitial lung disease
• People with diabetes where blood sugar levels are not well controlled
• People with significant protein detected in their urine, confirmed by a 24-hour urine test
• People with abnormal blood clotting results, a tendency to bleed, or who are currently receiving clot-dissolving or blood-thinning treatment (note: low-dose preventive heparin or low-dose aspirin may be permitted in certain circumstances — confirm with trial site)
• People who still have side effects from previous treatments that have not resolved, or who have not fully recovered from a previous surgery
• People who have epileptic seizures requiring treatment
• People who need regular systemic steroid medications above a low daily threshold, or other immune-suppressing drugs, within 7 days before starting the study drug (certain low-dose, inhaled, topical, or preventive uses may be permitted — confirm with trial site)
• People who have received live or weakened live vaccines within 30 days before the first study dose, or who plan to receive such vaccines during the study
• People who have difficulty taking oral medications, for example due to an inability to swallow or ongoing severe diarrhoea
• People with a history of substance misuse of mind-altering drugs that cannot be stopped, or people with a mental health disorder
• People with a history of severe allergic reactions to other monoclonal antibody therapies
• People who have had severe allergic reactions to anlotinib hydrochloride, bemosubaymab, or any ingredients in the study drugs
• People whose overall health condition, in the treating doctor's judgement, could put them at serious risk or prevent them from completing the study

Important: Always verify eligibility with the trial site directly before applying.